Research · October 29, 2026

United Therapeutics' Two FDA Clearances in Nine Days: One Inhaler, Two Lung Diseases

In nine days, United Therapeutics won FDA clearance under two investigational new drug applications for a single delivery platform. On October 19, 2026, the company announced clearance to proceed with the Phase 2 SUMMIT trial of treprostinil soft mist inhaler (SMI) in pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). On October 28, it announced a second clearance: a Phase 1 trial of Treprostinil-Iloprost SMI in pulmonary arterial hypertension (PAH). Two clearances, one inhaler platform, two lung diseases — and neither product is approved anywhere.

The first clearance is the further-advanced trial. The Phase 2, 16-week, double-blind SUMMIT study will evaluate the safety and tolerability of treprostinil SMI in approximately 40 patients with PH-COPD. Its secondary endpoints will evaluate efficacy on exercise capacity and N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker for heart failure, and eligible patients will be able to enroll in an open-label extension study for long-term safety, tolerability and efficacy. Assuming a successful outcome, United Therapeutics anticipates commencing a Phase 3 registration study in PH-COPD in 2028. The unmet need is the point: no therapy is currently specifically approved in the United States for PH-COPD, and the company estimates 400,000 to 800,000 people are living with the condition in the U.S. "Treprostinil SMI has the potential to be the first FDA-approved therapy specifically indicated for PH-COPD," the company said — a statement of potential, conditional on later trials and FDA approval. "PH-COPD is a serious, life-threatening condition with no approved treatments," said Leigh Peterson, Ph.D., head of pharmaceutical and xenograft development. "We believe that inhaled treprostinil, delivered via a soft mist inhaler, may benefit the carefully defined SUMMIT PH-COPD patient population by directly targeting the pulmonary vasculature."

The second clearance is earlier-stage but structurally different. The Phase 1, open-label, single ascending dose study of Treprostinil-Iloprost SMI will evaluate safety, tolerability and pharmacokinetics in healthy volunteers, and assuming a successful outcome, the company anticipates a Phase 2 study in PAH patients in 2027. The product combines two prostacyclin analogues, treprostinil and iloprost, delivered as an inhalation spray through a soft mist inhaler for as-needed use — episodic symptom relief for PAH patients who need a bridge between doses of their ongoing prostacyclin therapy during acute flare-ups. "If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for PAH," the company said. "Many people living with PAH experience moments when their symptoms flare despite their maintenance medication, and today they have no therapy designed specifically for those moments," said Ravi Patel, PharmD, Senior Vice President, Global Patient Safety and Strategic Clinical Development. PAH is a life-threatening disease affecting about 50,000 people in the United States and about 500,000 worldwide, and only a fraction of patients are treated.

The common thread is the device, not a new molecule. Treprostinil SMI uses a portable, handheld soft mist inhaler designed to deliver a preserved formulation of inhaled treprostinil solution in a single breath, in multiple dose strengths, four times daily, with each single-load cartridge designed to support up to two weeks of use and storage at room temperature. The company frames the inhaler as an advancement of treprostinil delivery devices that may address a wider range of tolerability profiles — including patients susceptible to cough and bronchospasm from inhaled therapies. It also plans to develop treprostinil SMI for PAH, pulmonary hypertension associated with interstitial lung disease, idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The platform framing matters: the bet here is that a better way to deliver an existing drug class can open indications where delivery itself has been the barrier.

What this is — and what it is not. An IND clearance is permission to run a clinical trial, not an approval, and both products are investigational-stage and not yet approved in any jurisdiction for any indication. The Phase 1 study tests healthy volunteers, not patients, so it will say nothing yet about whether the combination helps PAH patients. SUMMIT's primary endpoint is safety and tolerability — efficacy is secondary and unproven, which is the honest shape of a Phase 2 trial in a condition with no approved therapy. The "first" claims are company-stated potential, conditional on successful trials and FDA approval, and the 2027 and 2028 next-step dates are company anticipations assuming successful outcomes, not commitments. This article makes no efficacy claim, no approval-probability claim, and no revenue or market-size claim. United Therapeutics (Nasdaq: UTHR) does not currently carry a BlitzLab score — this is not a rescore.

For BlitzLab readers, the through-line is a platform bet rather than a single-drug bet: one inhaler design being tested across two indications, with the device itself — single-breath dosing, room-temperature storage, a tolerability profile aimed at patients who struggle with other inhaled therapies — as the differentiator rather than a new molecule. The watch points are sequential and public: the Phase 1 readout, then a Phase 2 study in PAH patients anticipated in 2027; SUMMIT's completion, then a Phase 3 registration study anticipated in 2028. Either path can stop at its next gate, and the gates themselves — safety first, efficacy second — are the story.

Sources